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Commentary
Within the practice of mental health and psychophar-
macology, therapeutic interventions should not focus 
only on the sole prescriber monitoring the effects of the 
psychotropic medications, but also on other members 
of the patient’s healthcare team. The decision to take an 
interprofessional approach as it relates to the initiation, 
monitoring, and management of drug therapy can have 
a significant impact on therapeutic outcomes. 
As it currently stands, psychopharmacology gener-
ally involves the examination of the effects that drugs 
can have on cognition, mood, behaviors, and think-
ing. Many of the psychotropic medications can prove 
to be instrumental in changing behavior for the better 
or alleviating problematic symptoms (Schatzberg, Cole, 
& DeBattista, 2010). Due to the sometimes unpredict-
able nature of psychotropic medications, the interac-
tion between psychiatry, pharmacy, and psychology is 
important in identifying potential adverse effects. The 
domains of psychopharmacology are generally rec-
ognized as hybrids of many disciplines that can apply 
anatomy, physiology, chemistry, biology, pharmacol-
ogy, and psychology when it comes to understanding 
how a particular drug can have an impact on a patient’s 
overall presentation (Stahl, 2008).
When it comes to treating mental disorders, there has 
been a longstanding discussion as to whether these are 
distinct clinical conditions, or arbitrary distinctions 
within a single diagnosis. For example, based on the 
American Psychiatric Association Diagnostic and Stati-
scal Manual of Mental Disorders, Fourth Edition, Text 
Revision (DSM-IV-TR), the similarities between a di-
agnosis of austim and Asperger Syndrome can make it 
challenging to discern one from the other. Careful anal-
ysis, consultation with other professionals, and clinical 
judgment can help to arrive at a final decision (Stahl, 
2008; APA, 2000).
These sometimes hazy diagnostic distinctions can 
prove to be quite challenging at times when it comes to 
selecting a pharmacotherapeutic intervention. An ef-
fective approach that can be taken is to elicit the expert 
opinion of healthcare professionals outside the prac-
titioner’s discipline who will be involved in the man-
agement of the patient. The integration of information 
from many professions is necessary to make a selection 
that can produce a positive therapeutic outcome for the 
patient. The “one size fits all” mentality cannot be en-
dorsed when it comes to drug selection, even for a spe-
cific diagnosis, because while a particular agent may be 
empirically supported because of the demonstration of 
efficacy in clinical trials other factors must be consid-
ered such as the individual’s past medical failures and 
successes, preferences, or co-existing medical condi-
tions (Stahl, 2008).
The treatment of mental illness is gradually gaining 
more attention among healthcare providers that work 
alongside mental health practitioners. As a result of the 
growing promotion of collaborative efforts as it relates 
to patient care, providers are beginning to formulate 
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more balanced therapeutic approaches that incorporate 
recommendations from other disciplines into their in-
terventions. For instance, a psychologist might only be 
comfortable using psychotherapeutic, nonpharmaco-
logical interventions to treat bipolar disorder. Yet this 
unidisciplinary approach completely disregards the 
beneficial effects that psychotropic medications have 
on the patient’s mood, cognition, and behavior. In this 
example, many psychologists might value their role as 
the alternative to allopathic pill pushers. Sometimes 
proper patient care demands psychopharmacological 
interventions alongside non-pharmaceutical interven-
tion. Both can ultimately benefit the patient in the long 
run (Preston & Johnson, 2009).
Practititioners are beginning to embrace an interpro-
fessional approach to the management and treatment 
of mental disorders because of its potential positive im-
pact on treatment outcomes (Doyle, Earnshaw, & Gal-
loway, 2003). A population of interest where this ap-
proach may prove to be significantly beneficial is with 
children and adolescents and the use of psychotropic 
medication. With a greater emphasis being placed on 
the use of psychotropic medications in children and 
adolescents, especially for the treatment of anxiety, 
obsessive-compulsive, bipolar, and depressive disor-
ders, the risk-versus-benefit of treatment is at times not 
adequately discussed within a multidisciplinary team 
(Hersen, Turner, & Biedel, 2007).
A review of the history of psychotropic medication uti-
lization among youths indicates that it was as high as 
6.3 percent, rivaling adult rates. The use of antidepres-
sents increased by 151 percent in the 7-12 age group 
and 580 percent in the under 6-year-old population 
between 1995 and 1999. Even though the treatment of 
mental disorders in children and adolescents is com-
mon, proper prescribing practices for the treatment of 
many of these disorders is still in its infancy (Sparks & 
Duncan, 2004).
When it comes to providing psychotropic medications 
to children, there are those conditions that require a 
moderate level of skill in management. Examples in-
clude obsessive-compulsive disorder, tic disorders like 
Tourette syndrome, and attention deficit hyperactivity 
disorder (ADHD). Yet greater skill is required in the 
treatment of anxiety disorders, depression, and aggres-
sive behavior associated with autism and intellectual 
disability. Some clinicians have the mindset that they 
have met the requirements to undertake this task and 
discount the importance of eliciting the expertise of 
other professionals (Hazell, 2005). Primary care physi-
cians have been identified as prescribing a large major-
ity of psychotropic medications to children and ado-
lescents. Most cases are out of their scope of practice, 
since many general practitioners have limited exposure 
to child and adolescent problems during their under-
graduate and postgraduate training (Hazell, 2005). 
The promotion of a more collaborative and integrated 
approach to prescribing efforts can minimize the harm 
associated with prescribing (Zwarenstein, Goldman,  & 
Reeves, 2009). The benefits of applying an interprofes-
sional approach to the management of psychotropic 
medications can only benefit patients who need this 
kind of care.
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